Investors Sell Shares of Gilead Sciences (GILD) on Strength (GILD)

Traders sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Monday. $102.92 million flowed into the stock on the tick-up and $268.28 million flowed out of the stock on the tick-down, for a money net flow of $165.36 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.82 for the day and closed at $80.14

A number of brokerages have issued reports on GILD. Mizuho set a $95.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, February 5th. Bank of America lifted their price target on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Leerink Swann cut their target price on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 7th. Morgan Stanley cut their target price on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Finally, Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $87.04.

The firm has a market capitalization of $106,210.00, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of -1.83 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the previous year, the company earned $2.70 EPS. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 6.24 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 59.77%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock worth $32,742,108 in the last ninety days. 1.30% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Welch Investments LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/investors-sell-shares-of-gilead-sciences-gild-on-strength-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply